Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.

$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal Jan 14 | 2020JPM 2020 Day 2: LLY, NVO, LVGO, SNY, PODD, ABT, and BDPurchase Blast
ADA cover image
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 03 | 2020Thoughts on ADA 2020 Standards of CarePurchase Blast
novo cover image
$599
Posted in: Basal Insulin, Bolus Insulin Jan 02 | 2020Novo Launches Insulin Savings ProgramPurchase Blast
novo cover image
$599
Posted in: GLP-1RA Dec 20 | 2019FENIX Analysis: Rybelsus LaunchPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Dec 19 | 2019Novo/UVA Partnership; Roche Decreases Eversense CGM Commitment; Lilly Insulin Pricing Open LetterPurchase Blast
lilly cover image
$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, SGLT2i Dec 17 | 2019Tirzepatide CVOT vs. Trulicity; Lilly 2020 Guidance SummaryPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Dec 16 | 2019Lilly/Dexcom Updated Partnership for CGMPurchase Blast
1 2 3 33

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.